

Preclinical development of an anti-neuroinflammatory drug for the treatment of Parkinson's disease



NEUROSCIENCE	Candidate
Product Type	Molecular degrader
Indication	Parkinson's disease
Target	Neuroinflammation
MoA(Mechanism of Action)	Targeted Protein Degradation (TPD)
Competitiveness	<ul style="list-style-type: none"> • New mode of action distinct from neurotoxic aggregates such as alpha-synuclein • Applicable to a variety of neurological disorders and inflammatory diseases • Novel modality (protein degrader) with high brain/plasma ratio • Proven efficacy in various animal models, indicating smooth translation to clinical phases • Clinical biomarkers for patient selection and early detection of efficacy • Potential combinational treatment option with antibody therapeutics
Development Stage	Candidate
Route of Administration	Oral Administration